Evaluation of ASC as a therapeutic target for Alzheimer's disease

Alzheimer s & Dementia 2026 Open access

Read full text
Authors: W. Brent Clayton, Joshua A. Kulas, Jiahui Liu, Nidhi Walia, Claudia Rangel‐Barajas, Travis Johnson, J. Jillian Zhang, Kun Huang, Andrew D. Mesecar, Jeffrey L. Dage, Bruce T. Lamb, Alan David Palkowitz
+1 more Timothy I. Richardson
DOI: 10.1002/alz.71104
Cited by: 1
References: 165

Abstract

Neuroinflammation is increasingly recognized as a central contributor to the pathogenesis and progression of Alzheimer's disease (AD). The apoptosis-associated speck-like protein containing a CARD (ASC), encoded by the PYCARD gene, plays a critical role in the formation of multiple inflammasomes, including NLRP3, a key mediator of inflammation signaling. Beyond its role in inflammasome formation, extracellular ASC specks have been shown to promote amyloid-β aggregation, showing a potential link between inflammation and plaque formation. In this review, we examine the role of ASC in AD pathology and highlight emerging tools to study ASC biology and strategies for ASC targeted drug discovery.

Fields of Study & Subjects

Inflammasome and immune disorders Alzheimer's disease research and treatments Tryptophan and brain disorders

Publication details

Journal / source
Alzheimer s & Dementia
Publisher
Wiley
Volume
22
Issue
1
Pages
e71104–e71104
Publication date
1 January 2026
Language
EN